Comment on Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
Mutation-targeted personalised medicine for cystic fibrosis / C. Colombo. - In: THE LANCET RESPIRATORY MEDICINE. - ISSN 2213-2600. - 2:11(2014 Nov), pp. 863-865. [10.1016/S2213-2600(14)70191-2]
Mutation-targeted personalised medicine for cystic fibrosis
C. ColomboPrimo
2014
Abstract
Comment on Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Colombo C Lancet Respir Med 2014.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
77.36 kB
Formato
Adobe PDF
|
77.36 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
